At the Advanced Light Source (ALS), researchers studied an antibody that was modified to activate a specific pathway of the immune system, demonstrating its value in killing tumor cells. The work provides a platform for disentangling the effects of different immune-system pathways and could lead to the design of improved cancer immunotherapies. The protein crystallography data in the study, which showed how an extreme twist in the modified antibody structure led to its selectivity, was collected at ALS Beamline 5.0.3 , which is part of the Biosciences’ Berkeley Center for Structural Biology; and at the Advanced Photon Source. Go to the ALS website to learn more.
Was this page useful?
Send
